Monty Aghazadeh, MD
Urology · Houston, TXNPI 1134439086
Payments from drug & device makers
Across 215 payments — averaging $212.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$39K
- Boston Scientific$2K
- Coloplast$1K
- KARL Storz Endoscopy-america$997
- Astellas Pharma US Inc$255
- Endo Pharmaceuticals Inc.$241
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$5001%
- Travel & lodging$5,18611%
- Food & beverage$6,43214%
- Education$33,65074%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 47 | $39,098 |
| Boston Scientific | 27 | $1,845 |
| Coloplast | 12 | $1,031 |
| KARL Storz Endoscopy-america | 4 | $997 |
| Astellas Pharma US Inc | 14 | $255 |
| Endo Pharmaceuticals Inc. | 12 | $241 |
| Pfizer | 11 | $235 |
| Johnson & Johnson(2 entities) | 11 | $219 |
| Procept Biorobotics Corporation | 3 | $195 |
| Merck | 9 | $173 |
| Myriad Genetic Laboratories, Inc. | 9 | $156 |
| Biotissue Holdings Inc. | 3 | $133 |
| Convatec Inc. | 5 | $113 |
| Antares Pharma, Inc. | 5 | $101 |
| Sumitomo Pharma America, Inc. | 4 | $94 |
| Ferring Pharmaceuticals Inc. | 4 | $87 |
| 180 Medical, Inc. | 4 | $87 |
| Endo USA, Inc. | 3 | $71 |
| Ambu Inc. | 3 | $68 |
| Teleflex LLC | 2 | $58 |
| Axonics, Inc. | 2 | $57 |
| AbbVie | 3 | $56 |
| Novo Nordisk | 2 | $55 |
| ABC Home Medical Supply, Inc. | 2 | $54 |
| Dendreon Pharmaceuticals LLC | 1 | $28 |
| Laborie Medical Technologies Corp. | 1 | $27 |
| Immunitybio, Inc. | 1 | $26 |
| Tolmar, Inc. | 1 | $24 |
| Medtronic | 1 | $23 |
| Blue Earth Diagnostics | 1 | $21 |
| Urovant Sciences Inc | 1 | $20 |
| Zyla Life Sciences, Inc. | 1 | $19 |
| Mission Pharmacal Company | 1 | $19 |
| GE HealthCare | 1 | $19 |
| Urogen Pharma, Inc. | 1 | $18 |
| Heron Therapeutics, Inc. | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Olympus America Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$37,036
- DA VINCI SP$1,500
- NEPHROSCOPE MIP M$621
- ALTIS$542
- GENERAL - THERAPIES$540
- GENERAL BPH$250
- AMS$232
- CMOS VIDEO URETEROSCOPE, 8.5 FR. X 675MM$222
- GENERAL KIDNEY STONE DISEASE$166
- Coloplast TFL Drive$145
- AquaBeam Robotic System$144
- CYSTO-URETHRO-FIBERSCOPE$136
- RESTORELLE$131
- Moses 550 DFL$112
- Moses 550 D\F\L$111
- FEMALE INCONTINENCE$102
How this compares
$45,769 in reported general payments places this provider in the 85th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 253 | $149,043 |
| Mirabegron ErMirabegron | 35 | $16,888 |
| GemtesaVibegron | 23 | $15,610 |
| Tamsulosin Hcl | 622 | $7,782 |
| Solifenacin Succinate | 57 | $2,846 |
| Silodosin | 20 | $1,976 |
| Testosterone | 12 | $1,929 |
| NitrofurantoinNitrofurantoin Macrocrystal | 101 | $1,901 |
| Testosterone Cypionate | 60 | $1,706 |
| Estradiol | 18 | $1,498 |
| Finasteride | 118 | $1,468 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 117 | $1,122 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 23 | $710 |
| Cefdinir | 40 | $537 |
| Oxybutynin Chloride ErOxybutynin Chloride | 54 | $403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $255 | $149,043253 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $94 | $15,61023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 urology providers in Texas.
Other urology in Houston
- Zvi SchiffmanHouston$17.8M
- Jose KaramHouston$5.7M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
- Brian ChapinHouston$1.1M
- Arun RaiHouston$1M
- Ashish KamatHouston$957K
- Donald GriffithHouston$732K
- Robert CornellHouston$695K
- John DavisHouston$669K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.